Anti-Rheumatic Rx
Zoster Vaccine in Rheumatic Disease: Dr. David Liew
Dr. David Liew reviews abstract #0452 presented at the ACR2020 annual meeting.
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 3 (#…
4 years ago
Dr. M. “Peggy” Crow’s #StateofArt lecture at #ACR20 reminds us that HCQ is the foundation of tx, to keep prednisone goal < 7.5mg/d, and that BEL works best in early dz (< 2 yrs) Summary slide provided. https://t.co/3LbWqwwOsr
Risk of HCQ Retinopathy: Dr. Kathryn Dao
Dr. Dao reviews abstract #0540 presented at the ACR annual meeting.
Risk of Skin Cancer with Methotrexate: Dr. Janet Pope
Dr. Janet Pope reviews abstract #1001 presented at the 2020 ACR annual meeting.
4 years ago
Both fat mass and fat free mass have an impact on the response to bDMARDs after 6 months of treatment in AS pts. No tx response changes w/ skeletal muscle mass, visceral fat as well as water components. #ABS1376 #ACR20 @RheumNow https://t.co/oIdE8qvJPp https://t.co/wlXFf8esey
Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two:
Targeting Plasmacytoid Dendritic Cells in Lupus…
4 years ago
Dr Lee reports on risk of melanoma and NMSC risk in RA in cohort study using propensity score matching. No difference in risk between MTX and HCQ overall. Increase BCC in MTX (HR 1.32) but less SCC (HR 0.77) @rheumnow #ACR20 Abstr#1001 https://t.co/LDWgfGK9LS
COVID and Rheumatic Disease Patients: Dr. Kevin Winthrop
Portland-based Dr. Kevin Winthrop from OHSU discusses Saturday ACR 2020 posters #0623 and #0629 related to COVID-19 and RA patients.
Subclinical Synovitis: Dr Eric Dein
Dr. Eric Dein reviews abstract #0481 presented at the 2020 ACR annual meeting, and reviews the Twitter poll he posted on whether clinicians would start DMARDs in this scenario.
Poster Hall